{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.67","value":"24.91"},{"groupId":"OG001","spread":"20.54","value":"24.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.09","value":"-3.79"},{"groupId":"OG001","spread":"17.51","value":"-2.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"Day 1: Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.95","value":"-4.08"},{"groupId":"OG001","spread":"16.01","value":"-3.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Day 1: Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.04","value":"-2.83"},{"groupId":"OG001","spread":"13.73","value":"-4.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Day 1: Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.54","value":"-3.33"},{"groupId":"OG001","spread":"21.40","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Day 1: Cycle 17"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Disease symptoms domain is one of the four domain scores. Disease symptoms domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on safety population evaluable for disease symptoms. Here, 'Number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}